Two snakebite antivenoms have potential to reduce Eswatini’s dependency upon a single, increasingly unavailable product: Results of preclinical efficacy testing
Fig 3
Protein profiles of the venom protein components of five Eswatini snake venoms.
A: Venom proteins separated by SDS-PAGE under reducing conditions and stained with Coomassie blue to show all proteinaceous components. B: Immunoblot using normal horse IgG used as primary antibody negative control. C: Immunoblot using SAIMR Polyvalent as primary antibody. D: Immunoblot using Panafrican (ICP) antivenom as primary antibody. E: Immunoblot using PANAF (PS&V) antivenom as primary antibody.